The doctor calls the weight and A1c drops impressive but notes Ozempic already has data showing fewer strokes and heart attacks.
Recap by typeshit. Post by @fromtheheart_md on Instagram.
6:25
Dr Almerie compares Lilly's experimental retatrutide with Mounjaro and talks through the case for switching versus holding off until it's approved.
He points to GLP-1 receptors in the hypothalamus, saying the medication boosts fullness signals and slows the stomach, which changes how hunger feels.
10:08
Weight loss doctor Bazgha Khalid goes through what the published trials actually show for Zepbound against Lilly's newer retatrutide.
Patients who took a GLP-1 receptor agonist before surgery did not lose more weight at one year, JAMA Surgery reports. The full study has the details.
Novo says the Denver data, Nov. 5 to 9, include a real-world comparison of Wegovy 2.4 mg and resmetirom in MASH patients, picked as a Poster of Distinction.
Net loss doubled to $183.2 million, and retail investors balked at CEO Brian Lian's estimate that VK2735 is about two and a half years from launch.
Loading…